Valuation: NetraMark Holdings Inc.

Market Cap 72.34M 51.26M 45.07M 41.95M 38.53M 4.92B 73.3M 499M 195M 2.43B 192M 188M 8.39B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 72.34M 51.26M 45.07M 41.95M 38.53M 4.92B 73.3M 499M 195M 2.43B 192M 188M 8.39B EV / Sales 2026 *
180x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
07-09 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
07-09 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
06-29 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
06-29 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
05-14 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
05-07 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
05-04 NetraMark Holdings Inc. Announces Executive Changes CI
04-22 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
04-20 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
04-09 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
03-25 NetraMark Collaborating With Italian Company To Analyze Phase II Oncology Dataset MT
03-25 Netramark Holdings Inc. and Fondazione Per La Medicina Personalizzata Announce Strategic Research Collaboration CI
03-25 NetraMark Brief: Announcing Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset MT
1 day-8.97%
1 week-11.25%
Current month+12.70%
1 month+14.52%
3 months-24.47%
6 months-36.04%
Current year-35.45%
1 week 0.69
Extreme 0.69
0.8
1 month 0.59
Extreme 0.59
0.95
Current year 0.59
Extreme 0.59
1.28
1 year 0.59
Extreme 0.59
1.8
3 years 0.16
Extreme 0.155
1.8
5 years 0.15
Extreme 0.15
2.25
10 years 0.15
Extreme 0.15
3.17
Manager TitleAgeSince
Chief Executive Officer - 16/02/2022
President - 03/07/2022
Director of Finance/CFO 57 17/07/2022
Director TitleAgeSince
Chairman 40 08/06/2025
Director/Board Member - -
Director/Board Member - 15/06/2022
Date Insider Type Main position Quantity % Market Cap.
26/06/26 Option

Chief Financial Officer

18,750 0.0202%
26/06/26 Option

Chief Financial Officer

-18,750 0.0202%
25/06/26 Option

Chief Executive Officer

449,375 0.4845%
Change 5-day change 1-year change 3-year change Capi.($)
-8.97%-11.25%-51.03%+173.08% 51.37M
+1.94%-3.28%-24.08%+17.65% 2,835B
+7.00%-2.46%-16.69%+714.43% 295B
+1.31%+4.24%+174.64%+991.44% 114B
+3.79%+2.63%+1.45%+44.15% 89.98B
+2.03%-4.31%+67.05%+130.09% 87.87B
+4.16%+2.78%-34.36%-13.32% 71.51B
+4.39%-1.23%-35.06%+73.26% 61.25B
+5.31%+2.08%+7.89%+62.80% 43.01B
+1.83%-9.07%-59.97%+27.72% 34.04B
Average +2.31%-4.34%+2.98%+222.13% 363.15B
Weighted average by Cap. +2.55%-3.60%-14.77%+109.01%

Financials

2026 *2027 *
Net sales 401K 284K 250K 232K 214K 27.25M 406K 2.76M 1.08M 13.45M 1.07M 1.04M 46.5M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume
27/07/26 CA$0.7100 -8.97% 62,784
24/07/26 CA$0.7800 +4.00% 5,500
23/07/26 CA$0.7500 -5.06% 2,000
22/07/26 CA$0.7900 -1.25% 25,740
21/07/26 CA$0.8000 0.00% 3,150

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AIAI Stock